Kangpu Biopharmaceuticals, Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Kangpu Completed Bridging Clinical Study of KPG-818 in China 2024-09-20 20:00
Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024 2024-06-10 20:00
FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC 2024-06-05 19:00
Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress) 2024-02-20 20:00
Kangpu Announces First Patient Dosed in the US Phase IIa Clinical Trial of NeoMIDES™ Molecular Glue KPG-818 in Systemic Lupus Erythematosus 2022-06-13 09:00
Kangpu Biopharmaceuticals Initiates Phase Ib/IIa Clinical Trial of KPG-818 in Systemic Lupus Erythematosus 2020-11-17 09:00
Kangpu to Present Two Posters at the 2020 American Association for Cancer Research (AACR) Annual Meeting 2020-06-17 21:00
Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S. 2019-10-11 13:00
1